NASDAQ:IOVA Iovance Biotherapeutics - IOVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.18 +0.23 (+2.89%) (As of 01/31/2023 11:12 AM ET) Add Compare Share Share Today's Range$7.99▼$8.1950-Day Range$5.62▼$8.1652-Week Range$5.42▼$18.73Volume646,820 shsAverage Volume5.05 million shsMarket Capitalization$1.29 billionP/E RatioN/ADividend YieldN/APrice Target$19.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Iovance Biotherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside144.7% Upside$19.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.47Based on 20 Articles This WeekInsider TradingAcquiring Shares$65.19 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.48) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsMedical Sector151st out of 1,055 stocksBiological Products, Except Diagnostic Industry26th out of 170 stocks 4.3 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.50, Iovance Biotherapeutics has a forecasted upside of 144.7% from its current price of $7.97.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IOVA. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 72.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.89. Previous Next 1.9 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Iovance Biotherapeutics this week, compared to 2 articles on an average week.Search InterestOnly 27 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,190,280.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Iovance Biotherapeutics is held by insiders.Percentage Held by Institutions96.78% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to decrease in the coming year, from ($2.48) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Iovance Biotherapeutics (NASDAQ:IOVA) StockIovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.Read More Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Stock News HeadlinesJanuary 29, 2023 | americanbankingnews.comFY2022 EPS Estimates for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Raised by AnalystJanuary 28, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Overweight at Piper SandlerJanuary 31, 2023 | Investing Trends (Ad)Without Graphite, There Would Be ZERO EV Batteries!Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.January 28, 2023 | americanbankingnews.comIovance Biotherapeutics, Inc. to Post Q1 2023 Earnings of ($1.66) Per Share, Oppenheimer Forecasts (NASDAQ:IOVA)January 27, 2023 | msn.comIovance gains as Piper sees approval for melanoma therapy this yearJanuary 26, 2023 | americanbankingnews.comTruist Financial Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $17.00January 25, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Iovance Biotherapeutics (IOVA), Elevance Health (ELV)January 24, 2023 | msn.comThe Latest Analyst Ratings for Iovance BiotherapeuticsJanuary 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 24, 2023 | finance.yahoo.comIovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%January 23, 2023 | finance.yahoo.comWhy Iovance Biotherapeutics Stock Soared 12% Higher TodayJanuary 23, 2023 | finance.yahoo.comIovance Biotherapeutics Provides Corporate, Clinical, and Regulatory UpdatesJanuary 13, 2023 | marketwatch.comTumor Infiltrating Lymphocyte (TIL) Market is booming in near Future 2023-2029January 12, 2023 | marketwatch.comNeoantigen Targeted Therapies Market 2023 : Incredible Possibilities, Growth Analysis and Forecast To 2028December 11, 2022 | finance.yahoo.comTrade Alert: The Independent Director Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), Wayne Rothbaum, Has Just Spent US$65m Buying 124% More SharesDecember 5, 2022 | marketwatch.comIovance Biotherapeutics Stock Up 20% After Director Buys 10M SharesDecember 5, 2022 | seekingalpha.comWhy did Iovance Biotherapeutics stock climb today? $65M insider buyDecember 1, 2022 | benzinga.com63K Reasons To Be Bullish On Iovance Biotherapeutics StockNovember 29, 2022 | benzinga.comIovance Biotherapeutics Recent Insider ActivityNovember 21, 2022 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)November 18, 2022 | markets.businessinsider.comIovance Declines Following FDA Feedback On Its Melanoma Drug LifileucelNovember 18, 2022 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on SAB Biotherapeutics (SABS)November 4, 2022 | msn.comRecap: Iovance Biotherapeutics Q3 EarningsNovember 2, 2022 | msn.comPreview: Iovance Biotherapeutics's EarningsOctober 10, 2022 | finance.yahoo.comIovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) TherapySeptember 27, 2022 | seekingalpha.comIovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum AcceleratesSeptember 10, 2022 | seekingalpha.comIOVA Iovance Biotherapeutics, Inc.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Company Calendar Last Earnings11/03/2022Today1/31/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees319Year Founded2013Price Target and Rating Average Stock Price Forecast$19.50 High Stock Price Forecast$38.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+138.4%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-342,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.45% Return on Assets-59.18% Debt Debt-to-Equity RatioN/A Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book2.07Miscellaneous Outstanding Shares157,840,000Free Float145,845,000Market Cap$1.29 billion OptionableOptionable Beta0.38 Social Links Key ExecutivesFrederick G. VogtPresident, CEO, Secretary & General CounselIgor P. BilinskyChief Operating OfficerJean-Marc BelleminCFO & Principal Accounting OfficerFriedrich Graf FinckensteinChief Medical OfficerKristin LanziVice President-Information TechnologyKey CompetitorsInhibrxNASDAQ:INBXAllogene TherapeuticsNASDAQ:ALLOVericelNASDAQ:VCELAdaptive BiotechnologiesNASDAQ:ADPTReplimune GroupNASDAQ:REPLView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 111,795 shares on 1/30/2023Ownership: 1.639%New York State Common Retirement FundBought 27,028 shares on 1/30/2023Ownership: 0.375%Rice Hall James & Associates LLCBought 388,024 shares on 1/27/2023Ownership: 1.154%ARK Investment Management LLCSold 1,497,353 shares on 1/24/2023Ownership: 0.519%Hennion & Walsh Asset Management Inc.Bought 77,253 shares on 1/12/2023Ownership: 0.107%View All Insider TransactionsView All Institutional Transactions IOVA Stock - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 1-year target prices for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they anticipate the company's share price to reach $19.50 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2023? Iovance Biotherapeutics' stock was trading at $6.39 at the beginning of the year. Since then, IOVA stock has increased by 24.4% and is now trading at $7.95. View the best growth stocks for 2023 here. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.01. What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). What is Iovance Biotherapeutics' stock symbol? Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA." Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (1.64%), Rice Hall James & Associates LLC (1.15%), ARK Investment Management LLC (0.52%), New York State Common Retirement Fund (0.37%), Peregrine Capital Management LLC (0.19%) and Hennion & Walsh Asset Management Inc. (0.11%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Iovance Biotherapeutics' stock price today? One share of IOVA stock can currently be purchased for approximately $7.95. How much money does Iovance Biotherapeutics make? Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.25 billion. The biotechnology company earns $-342,250,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. How many employees does Iovance Biotherapeutics have? The company employs 319 workers across the globe. How can I contact Iovance Biotherapeutics? Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com. This page (NASDAQ:IOVA) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.